The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

BACKGROUND: Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failure with reduced ejection fraction (HFrEF). Sodium-glucose c...

Descripción completa

Detalles Bibliográficos
Autores principales: Omar, Massar, Jensen, Jesper, Kistorp, Caroline, Højlund, Kurt, Videbæk, Lars, Tuxen, Christian, Larsen, Julie H., Andersen, Camilla F., Gustafsson, Finn, Køber, Lars, Schou, Morten, Møller, Jacob Eifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882292/
https://www.ncbi.nlm.nih.gov/pubmed/35219331
http://dx.doi.org/10.1186/s12933-022-01463-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882292/
https://www.ncbi.nlm.nih.gov/pubmed/35219331
http://dx.doi.org/10.1186/s12933-022-01463-2

Ejemplares similares